MDGL Stock News & Catalysts – Madrigal Pharmaceuticals

FEATURED

Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to an Ongoing Investigation of Possible Securities Law Violations

New

NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")

Summary

Nov 9, 2026, 1:20 PM ·Globe Newswire

RECENT

Madrigal Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Madrigal Pharmaceuticals (MDGL)

New

NEW YORK CITY, NY / ACCESS Newswire / November 9, 2026 / Madrigal Pharmaceuticals (NASDAQ:MDGL) shareholders lost $34.84 per share on November 3, 2026, when the stock fell 8.1% after the Company disclosed a

Nov 9, 2026, 10:25 AM ·ACCESS Newswire

Kaplan Fox Announces a Securities Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) - Investors Encouraged to Contact the Firm

New

New York, New York--(Newsfile Corp. - November 9, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")

Nov 9, 2026, 4:20 AM ·Newsfile

MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law

New

Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Madrigal Pharmaceuticals, Inc. ("Madrigal" or

Nov 8, 2026, 11:38 PM ·Business Wire

MDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

New

RADNOR, Pa., Nov. 07, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal

Nov 7, 2026, 11:41 AM ·Globe Newswire

Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

RADNOR, Pa., Nov. 6, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities

Nov 6, 2026, 8:07 PM ·PRNewswire

NASDAQ: MDGL INVESTIGATION ALERT: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Madrigal Pharmaceuticals, Inc.

Nov 6, 2026, 2:49 PM ·Business Wire

Lost Money on Madrigal Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 8.1% Share Price Drop

Investigation follows the November 3, 2026 disclosure regarding Madrigal Pharmaceuticals, Inc.; investors who lost money may have claims to recover their losses Investors who lost money on Madrigal Pharmaceuticals,

Nov 6, 2026, 11:00 AM ·Business Wire

Did You Lose Money on Madrigal Pharmaceuticals, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 8.1% Share Price Decline

Investigation comes after a November 3, 2026 report concerning Madrigal Pharmaceuticals, Inc.; shareholders who suffered losses may have claims to recover themInvestors who suffered losses on Madrigal Pharmaceuticals,

Nov 6, 2026, 9:00 AM ·Business Wire

Lost Money on Madrigal Pharmaceuticals, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 8.1% Stock Decline

Investigation centers on the November 3, 2026 news about Madrigal Pharmaceuticals, Inc.; investors with losses may have potential claims to recover them Madrigal Pharmaceuticals, Inc. ("Madrigal" or the

Nov 5, 2026, 3:18 PM ·Business Wire

Kaplan Fox & Kilsheimer LLP Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding Potential Securities Law Violations

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")

Nov 5, 2026, 2:30 PM ·Globe Newswire

Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra

In real-world studies, up to 93% of patients experienced improvement or stabilization in liver stiffness with ultrasound elastography, with many patients moving into lower liver stiffness categories one year after

Nov 5, 2026, 10:00 AM ·Globe Newswire

MADRIGAL PHARMACEUTICALS, INC. INVESTIGATION: MDGL Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ:MDGL). The

Nov 4, 2026, 6:09 PM ·Globe Newswire

Kaplan Fox & Kilsheimer LLP Encourages Madrigal Pharmaceuticals, Inc. (MDGL) Investors to Contact the Firm Regarding Potential Securities Law Violations

New York, New York--(Newsfile Corp. - November 4, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")

Nov 4, 2026, 11:15 AM ·Newsfile

Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates

Third-quarter 2026 Rezdiffra® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability Rezdiffra reaches a major milestone, achieving blockbuster

Nov 3, 2026, 7:00 AM ·Globe Newswire

Madrigal Pharmaceuticals, Inc. MDGL · News